Value
5.9/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 5.9 |
| Fwd P/E | 1.0 |
| PEG | 7.6 |
| Analyst target | 9.0 |
- ▸Forward P/E: 112.0x
- ▸PEG: 0.90
GYRE · Why this verdict
Why Gyre Therapeutics (GYRE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Gyre Therapeutics shows a highly favorable modeled asymmetry and a recovering technical setup, but value-trap signals from margin compression, a confirmed prior downtrend, material insider selling, and the absence of a clear trading edge together support the recommendation to consider reducing the position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine flags 2 of 5 value-trap signals, driven by operating margin compression to -30.2% and material insider selling of 18 transactions (0.12% of market cap), raising doubt about whether the apparent discount is a genuine opportunity or a value trap. Bear case | Operating margin should improve toward breakeven, above -10%, over the next 12 months if the compression reverses. | →Stable |
| CounterMargin compression at a clinical-stage or commercial-transition biotech can reflect deliberate reinvestment in R&D or commercialization rather than deteriorating unit economics, and can reverse quickly as revenue scales. | ||
The stock is in a confirmed downtrend, trading below its 200-day moving average with a slope of -3.2% per month, despite an overbought RSI near 74 from a bear-market rally. Momentum breakdown | The price should reclaim and hold above its 200-day moving average over the next 12 months if the downtrend reverses. | ↑Improving |
| CounterRising on-balance volume during the rally suggests genuine accumulation rather than a pure bear-market bounce, which could support a durable trend reversal rather than a fade back into the downtrend. | ||
The engine models an extremely favorable risk/reward skew, with an asymmetry ratio of 7.74 and 116.2% modeled upside against 15.0% downside, reflecting the speculative biotech setup's binary reward potential. Reward-to-risk math | Actual price upside should track toward the 116.2% modeled target over the next 12 months if the growth and pipeline thesis is realized. | ↓Deteriorating |
| CounterBinary biotech outcomes mean the analyst target driving this ratio could be invalidated entirely by a single clinical or regulatory setback, making the modeled asymmetry far less reliable than in a non-binary industry. | ||
Insiders have been material net sellers, with 18 separate sales totaling $952,875 over 90 days (0.116% of market cap), driving a bearish insider signal. Insider breakdown | Insider activity should turn neutral or bullish over the next 12 months if insiders regain confidence in the stock near current levels. | →Stable |
| CounterA pattern of 18 smaller sales rather than one large block can reflect routine, pre-scheduled selling plans (Rule 10b5-1) rather than a concentrated, high-conviction bearish view. | ||
The engine identifies no clear trading edge in the current setup, despite the recovery narrative and favorable modeled asymmetry, leaving the technical case less differentiated. Edge rationale | The engine should identify a clear positive edge type over the next 12 months if the recovery setup solidifies with a confirmed catalyst. | ↓Deteriorating |
| CounterThe absence of a labeled edge doesn't preclude a favorable outcome; it may simply reflect the engine's current classification criteria rather than the absence of any real opportunity. | ||
The engine flags 2 of 5 value-trap signals, driven by operating margin compression to -30.2% and material insider selling of 18 transactions (0.12% of market cap), raising doubt about whether the apparent discount is a genuine opportunity or a value trap.
→StableBear case
- Expectation
- Operating margin should improve toward breakeven, above -10%, over the next 12 months if the compression reverses.
CounterMargin compression at a clinical-stage or commercial-transition biotech can reflect deliberate reinvestment in R&D or commercialization rather than deteriorating unit economics, and can reverse quickly as revenue scales.
The stock is in a confirmed downtrend, trading below its 200-day moving average with a slope of -3.2% per month, despite an overbought RSI near 74 from a bear-market rally.
↑ImprovingMomentum breakdown
- Expectation
- The price should reclaim and hold above its 200-day moving average over the next 12 months if the downtrend reverses.
CounterRising on-balance volume during the rally suggests genuine accumulation rather than a pure bear-market bounce, which could support a durable trend reversal rather than a fade back into the downtrend.
The engine models an extremely favorable risk/reward skew, with an asymmetry ratio of 7.74 and 116.2% modeled upside against 15.0% downside, reflecting the speculative biotech setup's binary reward potential.
↓DeterioratingReward-to-risk math
- Expectation
- Actual price upside should track toward the 116.2% modeled target over the next 12 months if the growth and pipeline thesis is realized.
CounterBinary biotech outcomes mean the analyst target driving this ratio could be invalidated entirely by a single clinical or regulatory setback, making the modeled asymmetry far less reliable than in a non-binary industry.
Insiders have been material net sellers, with 18 separate sales totaling $952,875 over 90 days (0.116% of market cap), driving a bearish insider signal.
→StableInsider breakdown
- Expectation
- Insider activity should turn neutral or bullish over the next 12 months if insiders regain confidence in the stock near current levels.
CounterA pattern of 18 smaller sales rather than one large block can reflect routine, pre-scheduled selling plans (Rule 10b5-1) rather than a concentrated, high-conviction bearish view.
The engine identifies no clear trading edge in the current setup, despite the recovery narrative and favorable modeled asymmetry, leaving the technical case less differentiated.
↓DeterioratingEdge rationale
- Expectation
- The engine should identify a clear positive edge type over the next 12 months if the recovery setup solidifies with a confirmed catalyst.
CounterThe absence of a labeled edge doesn't preclude a favorable outcome; it may simply reflect the engine's current classification criteria rather than the absence of any real opportunity.
Per-dimension breakdown
Quality
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.7 |
| FCF quality | 3.3 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 5.6 |
- ▸FCF-positive despite GAAP loss (FCF margin 2%, FCF yield 0.3%)
- ▸Rule of 40: -0 (fail)
Growth
6.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.0 |
| EPS growth | 10.0 |
- ▸Declining revenue: -2%
Momentum
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 8.4 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -2.8%/30d — confirmed downtrend
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.8 |
| Analyst rating | 6.8 |
| Price target | 10.0 |
- ▸Light analyst coverage (3.0) — signal dampened
- ▸Analyst upside: 181%
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $869,948 (0.122% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.4 |
| quality rank | 5.2 |
| growth rank | 3.6 |
Technical
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.2 |
| support resistance | 2.2 |
| 52w position | 4.1 |
Risk (lower is worse)
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 0.0 |
| volatility | 0.8 |
| debt equity | 9.9 |
Catalyst
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:5.8>=5.5
- ASYMMETRY:9.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:85d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=5.8>=5.0 recovering
Reward-to-Risk
9.26
Upside
+139.0%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 67
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Sentiment at 7.1 and asymmetric R:R of 9.26.
The strongest dimensions are Sentiment at 7.1, Growth at 6.0, and Value at 5.9; the weakest are Technical at 2.5, Quality at 3.6, and Risk (lower is worse) at 4.5. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 9.26 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Value Trap Margin Compression
Trip ifOperating margin rises above -10%, from the current -30.2%, for 2 consecutive quarters.
- P2Confirmed Technical Downtrend
Trip ifMomentum score falls below 3.0, from the current 6.0, for 2 consecutive months, confirming the downtrend resumes.
- P3High Asymmetry Speculative Upside
Trip ifAsymmetry ratio falls below 2.0, from the current 7.74, as the price target or downside estimate resets.
- P4Material Insider Selling
Trip ifInsider signal flips to bullish with net insider buying exceeding $200,000 over a 90-day window.
- P5No Clear Trading Edge
Trip ifMomentum score falls below 4.0, from the current 6.0, for 2 consecutive months, without a new edge type being identified.